Aligos culls another hepatitis B asset, citing inconclusive efficacy data

Strike another hepatitis B drug candidate from Aligos Therapeutics’ once-stacked pipeline. The biotech kept up the cadence of program pruning by deciding against committing more cash to an siRNA prospect after getting a look at early-phase data.